What is the recommended dosing, contraindications, adverse effects, and alternative agents for nitrofurantoin in adults with uncomplicated cystitis and adequate renal function?

Nitrofurantoin for Uncomplicated Cystitis in Adults

Recommended Dosing

Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily for 5 days is the optimal first-line regimen for uncomplicated cystitis in adults with adequate renal function. 1

• The 5-day course achieves clinical cure rates of 88-93% and bacteriological cure rates of 81-92%, which is superior to single-dose fosfomycin (58% clinical resolution vs 70% for nitrofurantoin at 28 days). 1, 2
• A 7-day regimen (100 mg twice daily) is acceptable but provides no additional efficacy and increases adverse event risk by approximately 5% per extra day of treatment. 1, 3
• The alternative macrocrystal formulation at 50-100 mg four times daily for 5 days is less convenient but equally effective. 1

Absolute Contraindications

Do not prescribe nitrofurantoin if any of the following are present:

• Creatinine clearance <30 mL/min: The drug fails to achieve therapeutic urinary concentrations while accumulating systemically, causing irreversible peripheral neuropathy, pulmonary toxicity, and hepatotoxicity. 1
• Suspected pyelonephritis: Any fever >38°C, flank pain, costovertebral angle tenderness, nausea/vomiting, or systemic symptoms indicate upper tract infection—nitrofurantoin does not reach adequate renal tissue concentrations. 1
• Last trimester of pregnancy: Contraindicated in the final three months due to risk of hemolytic anemia in the newborn. 4

Critical Pitfall: The "Borderline" Upper Tract Infection

Never use nitrofurantoin for mild flank pain or low-grade fever—even subtle upper tract symptoms require a fluoroquinolone (ciprofloxacin 500 mg twice daily for 5-7 days) or trimethoprim-sulfamethoxazole (160/800 mg twice daily for 14 days if local resistance <20%). 1

Renal Function Considerations (CrCl 30-60 mL/min)

• Official guidelines contraindicate nitrofurantoin at CrCl <60 mL/min, but this cutoff is debated. 3
• Real-world evidence shows nitrofurantoin remains effective in 69% of patients with CrCl 30-60 mL/min when used against susceptible organisms, with only 2 of 26 failures attributable to renal insufficiency itself. 5
• In clinical practice, nitrofurantoin may be cautiously used at CrCl 30-60 mL/min if no alternatives exist, but it is absolutely contraindicated below 30 mL/min. 1, 5

Common Adverse Effects

• Nausea and headache occur in 5.6-34% of patients—the most frequent side effects. 1
• Serious pulmonary and hepatic toxicity are extremely rare (0.001% and 0.0003%, respectively) with short-course therapy. 1
• Peripheral neuropathy risk increases significantly with prolonged use or renal impairment. 1

Alternative First-Line Agents

When nitrofurantoin cannot be used, select alternatives based on this algorithm:

If Local E. coli Resistance to TMP-SMX is <20%:

• Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days achieves 90-100% clinical cure and 91-100% bacteriological cure. 6
• Do not use if the patient received TMP-SMX in the preceding 3 months or has recent travel to high-resistance areas. 1

If Resistance is ≥20% or Unknown:

• Fosfomycin trometamol 3 g single oral dose achieves 89-91% clinical cure but only 63-78% bacteriological cure—modestly inferior to nitrofurantoin. 1, 6, 2

Reserve Fluoroquinolones for Complicated Infections:

• Ciprofloxacin and levofloxacin should not be used for uncomplicated cystitis due to FDA warnings (tendon rupture, peripheral neuropathy, aortic dissection), rising resistance rates (24% in many communities), and collateral microbiome damage. 1
• Use fluoroquinolones only for pyelonephritis or when first-line agents fail. 1

Avoid Beta-Lactams for Empiric Therapy:

• Amoxicillin-clavulanate and cephalosporins demonstrate inferior efficacy compared to nitrofurantoin and should be reserved for culture-directed therapy. 1
• Never use amoxicillin or ampicillin alone due to globally high resistance. 1

Diagnostic Criteria for Uncomplicated Cystitis

Prescribe nitrofurantoin only when all of the following are present:

• Symptoms limited to dysuria, urgency, frequency, or suprapubic discomfort. 1
• No fever >38°C, flank pain, nausea/vomiting, or costovertebral angle tenderness. 1
• Non-pregnant, pre-menopausal patient with no known urological abnormalities. 1
• Adequate renal function (CrCl ≥30 mL/min). 1

Follow-Up and Treatment Failure

• Do not obtain routine post-treatment urine cultures in asymptomatic patients. 1
• If symptoms persist after therapy or recur within 2 weeks, obtain urine culture with susceptibility testing and retreat with a 7-day regimen using a different agent. 1
• Never treat asymptomatic bacteriuria in non-pregnant patients or those not undergoing urological procedures. 1

Special Populations

Elderly Patients:

• Nitrofurantoin is appropriate for uncomplicated cystitis in elderly patients with CrCl ≥30 mL/min. 1
• Avoid fluoroquinolones, which carry heightened risks of tendon rupture and CNS toxicity in this population. 1

Men with Cystitis:

• Limited evidence supports 7-14 days of therapy for acute UTI in men. 1
• Do not use nitrofurantoin if prostatitis is suspected—the drug does not penetrate prostatic tissue. 1

Women with Diabetes:

• Treat similarly to women without diabetes when no voiding abnormalities are present. 7

Patients on Fluconazole:

• Nitrofurantoin has no clinically significant drug-drug interactions with azole antifungals and remains the optimal choice. 1

Antimicrobial Stewardship Considerations

• Nitrofurantoin is classified as an "Access" antibiotic by the WHO AWaRe framework, reflecting its favorable resistance profile and suitability for first-line empiric therapy. 1
• Despite 60+ years of use, nitrofurantoin maintains 95-98% susceptibility against E. coli, making it a critical stewardship tool. 1
• Preserving fluoroquinolone efficacy by restricting their use to appropriate upper-tract infections is a key stewardship goal. 1